Ligand strikes deal to buy struggling Neurogen

Three months after slashing half of its workforce and shelving research work, Neurogen has agreed to be bought out by Ligand Pharmaceuticals for $11 million in stock and the chance to earn millions more in milestones. The acquisition deal gives Ligand a partnership with Merck covering a pain therapy now in clinical trials. Release | Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.